Palisade Bio
PALI
124 hedge funds and large institutions have $362M invested in Palisade Bio in 2026 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 33 increasing their positions, 24 reducing their positions, and 21 closing their positions.
138% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 21
38% more capital invested
Capital invested by funds: $262M → $362M (+$101M)
38% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 24
29% more funds holding
Funds holding: 96 → 124 (+28)
9.77% more ownership
Funds ownership: 90.12% → 99.89% (+9.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$25.7M |
| 2 |
BlackRock
New York
|
+$16.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.53M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.36M |
| 5 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$3.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$12.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$4.64M |
| 3 |
Morgan Stanley
New York
|
-$4.09M |
| 4 |
Goldman Sachs
New York
|
-$3.53M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.75M |
PALI Hedge Fund Activity: Q2 2026 in Review
124 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q2 2026, worth a combined $362M — up 38% from $262M a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new PALI positions and 21 closed out — a net gain of 29 holders — while 33 added to existing stakes and 24 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $25.7M. The largest seller was Commodore Capital, exiting entirely with an estimated $12.6M sold.
- 124 institutional investors held Palisade Bio (PALI) as of Q2 2026, up from 96 in Q1 2026.
- Funds reported $362M of Palisade Bio stock for Q2 2026, up 38% quarter-over-quarter.
- 50 funds opened new Palisade Bio positions in Q2 2026 and 21 closed out, a net change of +29 holders.
- The largest Palisade Bio buyer in Q2 2026 was Soleus Capital Management, an estimated $25.7M added.
- The largest Palisade Bio seller in Q2 2026 was Commodore Capital, an estimated $12.6M sold.
Based on aggregated 13F filings for Q2 2026.